Inflammation reduction in epidermal tissue

"Inflammation reduction in epidermal tissue" is not a specific molecule, receptor, or canonical therapeutic target. Rather, it describes a biological process or therapeutic goal relevant to many skin diseases. Multiple molecular targets and pathways are involved in regulating inflammation within the epidermis. Key regulators include the Epidermal Growth Factor Receptor (EGFR), mitogen‐activated protein kinases such as ERK1/2 and p38 MAPK, and various circulating proteins like RARRES2, SERPINC1, GALK1, ECM1, PPID, and IL1RL1[1][2][3]. These molecules modulate chemokine expression in keratinocytes and influence immune cell recruitment during inflammatory responses[1][3]. Numerous drugs—such as EGFR inhibitors—can affect these pathways but may also cause adverse skin inflammation by disrupting homeostatic signaling[3]. Because "inflammation reduction in epidermal tissue" is not itself a discrete molecular entity but rather an outcome influenced by many targets and mechanisms across different disease contexts[2], it cannot be classified as a single canonical target. Additional notes: If you are seeking structured information on specific molecular targets involved in reducing inflammation within the epidermis—such as EGFR or ERK1/2—please specify which molecule or pathway of interest so that detailed data can be provided accordingly.